Secondary Progressive Multiple Sclerosis (SPMS): Diagnosis, Symptoms & Therapy
SPMS follows relapsing-remitting MS (RRMS), marked by steady neurological worsening independent of relapses. ~50% of RRMS patients transition within 10–20 years.
Clinical Features
- Gradual accumulation of disability (EDSS increase).
- Pyramidal signs: weakness, spasticity, hyperreflexia.
- Cerebellar: ataxia, intention tremor.
- Sensory: numbness, paresthesia.
- Bladder/bowel dysfunction, cognitive decline, fatigue, depression.
Diagnosis
Clinical: ≥6 months of progressive worsening without relapses (or with overlapping relapses = active SPMS). Supported by MRI (new T2 lesions, atrophy) and CSF (oligoclonal bands).
Disease-Modifying Therapies (DMTs)
- Active SPMS (with relapses/new MRI activity): Siponimod, ozanimod, cladribine, alemtuzumab, natalizumab, anti-CD20 (ocrelizumab, ofatumumab).
- Non-active SPMS: Limited options; siponimod approved based on EXPAND trial showing disability slowing.
Rehabilitation & Supportive Care
- Physical/occupational/speech therapy for function maintenance.
- Assistive devices (cane, walker, wheelchair).
- Symptom management: spasticity (baclofen, botox), neuropathic pain, bladder issues.
- Psychosocial: counseling, support groups, vocational rehab.
Early SPMS recognition enables timely DMT initiation to preserve independence.
Multiple Sclerosis - Related Articles
- Multiple Sclerosis Relapse: Symptoms, What to Do & When to See a Doctor
- Exercise for Multiple Sclerosis: Benefits & Practical Tips
- Toxic Metals & Multiple Sclerosis: A Potential Link
- Multiple Sclerosis with Negative Spinal Fluid: Diagnostic Nuances
- Understanding Multiple Sclerosis & Trigeminal Neuralgia: Symptoms & Causes
- Scurvy Prognosis: Recovery Timeline and Risks of Untreated Cases
- Understanding and Managing Fatigue in Multiple Sclerosis (MS)
